Drug Trial Radar · NCT05648591
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
May 24, 2023
Primary completion
Dec 31, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Vanda PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Dec 13, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment.
Conditions
- Schizophrenia
- Bipolar I Disorder
Interventions
IloperidoneDrug
oral tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-emergent adverse events (TEAEs) in the treatment period.Time frame: 1 year
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Vanda Investigational Site
Dothan, Alabama · Recruiting
Vanda Investigational Site
Little Rock, Arkansas · Recruiting
Vanda Investigational Site
Denver, Colorado · Recruiting
Vanda Investigational Site
Atlanta, Georgia · Recruiting
Vanda Investigational Site
Atlanta, Georgia · Recruiting
Vanda Investigational Site
Decatur, Georgia · Recruiting
Vanda Investigational Site
Kinston, North Carolina · Recruiting
Vanda Investigational Site
Cincinnati, Ohio · Recruiting
Vanda Investigational Site
Garfield Heights, Ohio · Recruiting
Vanda Investigational Site
Westlake, Ohio · Recruiting
Vanda Investigational Site
Everett, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.